KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) EBITDA: 2009-2024

Historic EBITDA for Exact Sciences (EXAS) over the last 16 years, with Dec 2024 value amounting to -$1.0 billion.

  • Exact Sciences' EBITDA rose 35.17% to -$25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 316.35%. This contributed to the annual value of -$1.0 billion for FY2024, which is 387.74% down from last year.
  • As of FY2024, Exact Sciences' EBITDA stood at -$1.0 billion, which was down 387.74% from -$215.0 million recorded in FY2023.
  • Exact Sciences' 5-year EBITDA high stood at -$215.0 million for FY2023, and its period low was -$1.0 billion during FY2024.
  • Moreover, its 3-year median value for EBITDA was -$593.5 million (2022), whereas its average is -$619.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 63.77% in 2023, then slumped by 387.74% in 2024.
  • Exact Sciences' EBITDA (Yearly) stood at -$767.7 million in 2020, then dropped by 11.46% to -$855.7 million in 2021, then spiked by 30.64% to -$593.5 million in 2022, then soared by 63.77% to -$215.0 million in 2023, then plummeted by 387.74% to -$1.0 billion in 2024.